China Resources Boya Bio-pharmaceutical GroupLtd Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

China Resources Boya Bio-pharmaceutical GroupLtd wird ein jährliches Gewinn- und Umsatzwachstum von 44.4% bzw. 13.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8% betragen.

Wichtige Informationen

44.4%

Wachstumsrate der Gewinne

44.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	43.6%
Wachstumsrate der Einnahmen	13.9%
Zukünftige Eigenkapitalrendite	8.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

Nov 01

A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Oct 01

Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Sep 12

Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

Jul 25

China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

Jun 12

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Apr 26

Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

Apr 22

China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

Apr 01

What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Mar 31

Gewinn- und Umsatzwachstumsprognosen

SZSE:300294 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,305	698	690	689	6
12/31/2025	2,051	614	621	591	7
12/31/2024	1,727	510	702	815	2
9/30/2024	1,707	186	246	378	N/A
6/30/2024	2,007	228	376	460	N/A
3/31/2024	2,295	219	458	543	N/A
12/31/2023	2,652	237	554	642	N/A
9/30/2023	2,866	478	609	745	N/A
6/30/2023	2,901	479	592	761	N/A
3/31/2023	2,910	499	647	797	N/A
12/31/2022	2,759	432	458	596	N/A
9/30/2022	2,722	439	459	549	N/A
6/30/2022	2,754	426	525	578	N/A
3/31/2022	2,681	347	1,152	1,208	N/A
12/31/2021	2,651	345	1,277	1,345	N/A
9/30/2021	2,667	360	1,281	1,410	N/A
6/30/2021	2,586	297	1,333	1,474	N/A
3/31/2021	2,528	265	669	808	N/A
12/31/2020	2,513	260	576	719	N/A
9/30/2020	2,664	332	533	622	N/A
6/30/2020	2,755	374	134	228	N/A
3/31/2020	2,867	433	-59	38	N/A
12/31/2019	2,909	426	-203	-115	N/A
9/30/2019	2,867	501	-369	-286	N/A
6/30/2019	2,735	491	-214	-140	N/A
3/31/2019	2,609	486	-110	-34	N/A
12/31/2018	2,388	469	-79	35	N/A
9/30/2018	2,307	419	21	137	N/A
6/30/2018	2,012	390	N/A	115	N/A
3/31/2018	1,732	362	N/A	-3	N/A
12/31/2017	1,390	357	N/A	-24	N/A
9/30/2017	1,132	316	N/A	21	N/A
6/30/2017	1,085	324	N/A	94	N/A
3/31/2017	994	301	N/A	168	N/A
12/31/2016	947	272	N/A	199	N/A
9/30/2016	839	227	N/A	146	N/A
6/30/2016	720	187	N/A	143	N/A
3/31/2016	615	145	N/A	149	N/A
12/31/2015	543	152	N/A	147	N/A
9/30/2015	498	138	N/A	114	N/A
6/30/2015	472	130	N/A	95	N/A
3/31/2015	452	130	N/A	95	N/A
12/31/2014	438	104	N/A	122	N/A
9/30/2014	366	96	N/A	112	N/A
6/30/2014	321	89	N/A	113	N/A
3/31/2014	278	85	N/A	93	N/A
12/31/2013	245	82	N/A	89	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300294Das prognostizierte Gewinnwachstum (44.4% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300294Die Erträge des Unternehmens (44.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (25.9% pro Jahr).

Hohe Wachstumserträge: 300294Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300294Die Einnahmen des Unternehmens (13.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 300294Die Einnahmen des Unternehmens (13.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300294Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8%).

China Resources Boya Bio-pharmaceutical GroupLtd Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 8.1% to CN¥35.09

Consensus revenue estimates fall by 17%

Price target decreased by 8.8% to CN¥32.01

Price target decreased by 10% to CN¥36.93

Price target increased to CN¥40.30

Price target decreased to CN¥31.94

Recent updates

Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.27 in 3Q 2023)

China Resources Boya Bio-Pharmaceutical Group Co.,Ltd Announces 2024 Interim Profit Distribution for A Shares, Payable on 25 October 2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

China Resources Boya Bio-pharmaceutical Group Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

China Resources Boya Bio-pharmaceutical Group Co.,Ltd Approves Interim Cash Dividend for the 2024

Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Now 23% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.31 in 2Q 2023)

Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) agreed to acquire 77.35% stake in Green Cross Hk Holdings Limited from Green Cross Holdings Corporation (KOSE:A005250) for approximately KRW 270 billion.

China Resources Boya Bio-pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Aug 24, 2024

China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

Price target increased by 8.1% to CN¥35.09

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Dividend increased to CN¥0.30

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.34 in 1Q 2023)

Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

China Resources Boya Bio-pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 24, 2024

Consensus revenue estimates fall by 17%

Price target decreased by 8.8% to CN¥32.01

China Resources Boya Bio-pharmaceutical Group Co.,Ltd, Annual General Meeting, Apr 12, 2024

Full year 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.86 in FY 2022)

Now 22% undervalued after recent price drop

China Resources Boya Bio-pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Mar 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.28 in 3Q 2022)

China Resources Boya Bio-pharmaceutical Group Co.,Ltd to Report Q3, 2023 Results on Oct 25, 2023

Price target decreased by 10% to CN¥36.93

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.34 in 2Q 2022)

China Resources Boya Bio-pharmaceutical Group Co., Ltd. to Report Q2, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.86 (vs CN¥0.79 in FY 2021)

Price target increased to CN¥40.30

Price target decreased to CN¥31.94

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.22 in 2Q 2021)

China Resources Boya Bio-pharmaceutical Group Co., Ltd. announces the implementation of cash dividend for 2021, Payable on 13 May 2022

Price target decreased to CN¥36.56

High number of new and inexperienced directors

China Resources Boya Bio-Pharmaceutical Group Co., Ltd. Approves Cash Dividend For 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.15 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.15 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.23 in 1Q 2020)

China Resources Pharmaceutical Holdings Company Limited completed the acquisition of 16% stake in Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) from ShenZhen GTJA Investment Group Co., Ltd.

Investor sentiment deteriorated over the past week

Boya Bio-Pharmaceutical Group Co.,Ltd Announces Cash Dividend for 2020, Payable on 26 May 2021

Boya Bio-Pharmaceutical Group Co.,Ltd Approves Cash Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥1.00 in FY 2019)

Boya Bio-Pharmaceutical Group Co.,Ltd Announces Final Dividend Profit Distribution Proposal for 2020

Investor sentiment improved over the past week

New 90-day low: CN¥23.37

Boya Biology Announces Election of Directors

Investor sentiment deteriorated over the past week

New 90-day low: CN¥33.50

New 90-day low: CN¥34.09

New 90-day low: CN¥34.45

Revenue and earnings miss expectations

Third quarter 2020 earnings released: EPS CN¥0.15

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

Boya Bio-pharmaceutical Group Co.,Ltd announced that it expects to receive CNY 2.72388007 billion in funding from China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical Group Limited (SEHK:3320) entered into a letter of intent to acquire an unknown stake in Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) from ShenZhen GTJA Investment Group Co., Ltd.

New 90-day low - CN¥36.90